Literature DB >> 8947281

Cerebral metabolism in a case of multiple sclerosis with acute mental disorder.

M Blinkenberg1, K Rune, A Jønsson, S Holm, C V Jensen, O B Paulson, P S Sørensen.   

Abstract

Acute mental disorder in early Multiple Sclerosis (MS) is rare and little is known about the structural and metabolic changes in this relation. We present an MS patient with discrete motor and sensory deficits, who developed severe behavioral changes over a period of nine months during the initial course of the disease. The cerebral metabolic rate of glucose (CMRglc) was measured using positron emission tomography (PET), and the patient underwent MRI as well as a comprehensive battery of neuropsychological tests. Significantly reduced values of CMRglc were found bilaterally in the frontal and temporal cortex, the putamen, the thalamus and the hippocampus. The MRI revealed progression of MS lesions in the frontal lobes during the development of mental symptoms. Neuropsychological examination showed wide spread cognitive dysfunction, and a pronounced frontal lobe syndrome. The study demonstrates the remote metabolic effects of lesions affecting subcortical neural connections in an MS patient with severe cognitive dysfunction.

Entities:  

Mesh:

Year:  1996        PMID: 8947281     DOI: 10.1111/j.1600-0404.1996.tb07071.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  3 in total

1.  Metabolic disturbances in the gray matter of the human brain in autoimmune demyelinating disease of the nervous system and their contribution to the symptomatology of the disease.

Authors:  L N Prakhova; A G Il'ves; G V Kataeva; M S Rudas; N A Totolyan; I D Stolyarov
Journal:  Dokl Biol Sci       Date:  2002 Sep-Oct

2.  Variants of personality maladaptation in patients with multiple sclerosis.

Authors:  T N Reznikova; I Yu Terent'eva; G V Kataeva
Journal:  Neurosci Behav Physiol       Date:  2007-10

Review 3.  PET imaging in multiple sclerosis.

Authors:  Daniele de Paula Faria; Sjef Copray; Carlos Buchpiguel; Rudi Dierckx; Erik de Vries
Journal:  J Neuroimmune Pharmacol       Date:  2014-05-09       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.